中国现代医学杂志2025，Vol.35Issue(5)：46-52,7.DOI:10.3969/j.issn.1005-8982.2025.05.008
蛋白水解靶向嵌合体技术在恶性肿瘤治疗中的研究进展
Research progress on proteolysis-targeting chimera(PROTAC)technology in the treatment of malignant tumors
摘要
Abstract
Traditional cancer treatment modalities primarily include surgery,radiotherapy,and chemotherapy.In recent years,with an in-depth understanding of cancer pathogenesis,immunotherapy and targeted therapy have also emerged as pivotal clinical strategies for cancer management.However,radiotherapy and chemotherapy exhibit substantial toxic side effects on normal cells,while immunotherapy and targeted therapies are prone to drug resistance,thereby diminishing therapeutic efficacy.To address these challenges,targeting specific pathogenic proteins has become a focal area of research.The advent of proteolysis-targeting chimeras(PROTACs)has introduced a promising therapeutic avenue for cancer treatment.PROTACs represent a novel class of agents designed to eliminate target proteins by hijacking the ubiquitin-proteasome system(UPS)to induce ubiquitination and degradation of the target protein.Compared to small-molecule inhibitors,PROTACs not only specifically degrade pathogenic target proteins but also demonstrate unique advantages in reducing drug toxicity and adverse effects,overcoming drug resistance,and targeting"undruggable"oncogenic proteins.This review summarizes recent advancements in PROTAC technology for malignant tumors,evaluates its strengths and limitations in therapeutic applications,and provides insights to inform future research in cancer therapy.关键词
蛋白水解靶向嵌合体/恶性肿瘤/不可成药/靶向治疗Key words
proteolysis-targeting chimeras/malignant tumors/undruggable targets/targeted therapy分类
临床医学引用本文复制引用
刘小凤,陈元静,周娟红,席毓淋,杜盟盟,刘会玲..蛋白水解靶向嵌合体技术在恶性肿瘤治疗中的研究进展[J].中国现代医学杂志,2025,35(5):46-52,7.基金项目
国家自然科学基金(No:82260557) （No:82260557）
甘肃省人民医院院内科研基金项目(No:23GSSYF-8) （No:23GSSYF-8）
